Articles by Scott Milligan, PhD

Changing Demographics Among Populations Prescribed HCV Treatment, 2013-2017
ByNaoky Tsai, MD,Bruce Bacon, MD,Michael Curry, MD,Steven L. Flamm, MD,Scott Milligan, PhD,Nicole Wick, AS,Zobair Younossi, MD,Nezam Afdhal, MD From 2013 to 2017, the population of US patients prescribed treatment for chronic hepatitis C virus (HCV) changed, becoming predominantly treatment-naïve and having received care in nonacademic centers.

Physician Behavior Impact When Revenue Shifted From Drugs to Services
ByBruce Feinberg, DO,Scott Milligan, PhD,Tim Olson, MBA,Winston Wong, PharmD,Daniel Winn, MD,Ram Trehan, MD,Jeffrey Scott, MD Shifting physician revenue from drug sales to cognitive services for mature pathways providers did not affect practice behavior in this payer-sponsored Oncology Medical Home.

Third-Party Validation of Observed Savings From an Oncology Pathways Program
ByBruce A. Feinberg, DO,Scott Milligan, PhD,Joseph Cooper, BS,Winston Wong, PharmD,Daniel Winn, MD,Neil Schneider, ASA, MAAA,Sheamus Parkes, FSA, MAAA,Jeffrey Scott, MD 
Implementation of Cancer Clinical Care Pathways
ByBruce A. Feinberg, DO,James Lang, PharmD, MBA,James Grzegorczyk, MS, RPh,Donna Stark, RPh, MBA,Thomas Rybarczyk, RN, BSN,Thomas Leyden, MBA,Joseph Cooper,Thomas Ruane, MD,Scott Milligan, PhD 
Implementation of Cancer Clinical Care Pathways: A Successful Model of Collaboration Between Payers and Providers
ByBruce A. Feinberg, DO,James Lang, PharmD, MBA,James Grzegorczyk, MS, RPh,Donna Stark, RPh, MBA,Thomas Rybarczyk, RN, BSN,Thomas Leyden, MBA,Joseph Cooper,Thomas Ruane, MD,Scott Milligan, PhD,Philip Stella, MD,Jeffrey A. Scott, MD A statewide collaboration between payers and providers to create a cancer clinical care pathways program is successful.